2018 IPO

Rubius Therapeutics Stock

Rubius is developing a new class of drugs, Red-Cell Therapeutics™,

Sign up today and learn more about Rubius Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.



Notable Investors

Flagship Pioneering


Cambridge MA, US

Total Funding


About Rubius Therapeutics Stock

VentureLabs has been creating breakthrough companies since 2000. It is the first institution dedicated to entrepreneurial innovation, where discovery, invention and entrepreneuring are performed simultaneously by a world-class team of scientists, innovators and professional entrepreneurs. VentureLabs innovates, invents, launches and builds startups through a unique, systematic approach that produces best-in-class companies based on in-house innovations. VentureLabs has started 35 life science and technology companies, including Joule Unlimited, Seres Therapeutics (NASDAQ: MCRB), Pronutria Biosciences, Symbiota and Moderna Therapeutics.


Funding History

December 2015$25.0M
June 2017$120M


Senior Vice President, Corporate Development

Nathan Dowden

Co-Founder and Chief Innovation Officer

Avak Kahvejian

Chief Scientific Officer

Robert J Deans


Torben Straight Nissen


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: